BeiGene
2025.03.10
10:14
Hong Kong stocks fluctuated downward, with the Hang Seng Index falling by 1%.
Hong Kong stocks fluctuated downward, with the Hang Seng Index falling by 1% and the Hang Seng Technology Index falling by more than 1.5%. BeiGene and SMIC fell by more than 3%.
09:43
BeiGene's A-shares and H-shares both fell in early trading, with A-shares falling more than 5% and Hong Kong stocks falling nearly 3%.
09:41
BeiGene fell more than 5% during the session
BeiGene fell more than 5% during the session and is now trading at 218.79 yuan.
2025.03.06
05:35
FTSE China A50 Index to include Cambrian, China Unicom and Guotai Junan
On March 5, FTSE Russell announced quarterly review changes to the FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, and FTSE China A400 Index. The change will take effect after the close of trading on Friday, March 21, 2025. Specifically, the FTSE China A50 Index, which has attracted the most attention in the market, will include Cambrian-U, China Unicom, and Guotai Junan; China General Nuclear Power, Yili Group, and Luzhou Laojiao will be removed. BeiGene-U, SAIC Group, Seres, Inovance, and ZTE Corporation are on the list of reserve stocks for the FTSE China A50 Index. The reserve list will take effect immediately until the next quarterly review of the constituent stocks. If one or more constituent stocks are deleted, the reserve stocks will be selected.
2025.02.28
09:59
BeiGene's A-share price once surged by more than 9.5%, and its share price hit a record high.
2025.02.27
19:12
BeiGene: Revenue in 2025 is expected to be between RMB 35.2 billion and RMB 38.1 billion
BeiGene announced that its operating income in 2025 is expected to be between RMB 35.2 billion and RMB 38.1 billion. The strong growth in revenue is mainly due to BeiGene's leading position in the United States and its continued expansion in Europe and other important markets around the world. At the same time, based on the company's product portfolio and improved production efficiency, the gross profit margin is expected to be in the median range of 80% to 90% in 2025. It is expected that the total R&D expenses, sales and administrative expenses in 2025 will be between RMB 29.5 billion and RMB 31.9 billion.
2025.02.26
16:09
BeiGene responds to the departure of its former Greater China CFO: Recruitment of a successor will be initiated as soon as possible
On February 26, media reported that Eric Huang, the chief financial officer (CFO) of Greater China and the head of global technical operations finance of BeiGene, had resigned. Public information shows that before joining BeiGene, Eric Huang worked at Novartis from 2007 to 2020. On the afternoon of February 26, the reporter learned from BeiGene that Eric Huang, the former chief financial officer of Greater China and the head of global technical operations finance, had indeed resigned recently to seek external development opportunities. The company will start recruiting his successor as soon as possible.
15:00
BeiGene Greater China CFO Huang Zhi has resigned
On February 26, people close to BeiGene revealed that Huang Zhi, BeiGene's chief financial officer for Greater China and head of global technical operations finance, had resigned. Before joining BeiGene, Huang Zhi worked at Novartis from 2007 to 2020. The current global CFO of BeiGene is Aaron Rosenberg.
2025.02.24
10:10
Hong Kong-listed biopharmaceutical stocks continued to decline, with the WuXi Group falling sharply. WuXi Associates (02268.HK) fell more than 12%, WuXi Biologics (02269.HK) and WuXi AppTec (02359.HK) both fell more than 9%, Tiger Pharmaceuticals (03347.HK) fell nearly 5%, Rongchang Biopharma (09995.HK) and BeiGene (06160.HK) both fell more than 2%.
2025.02.21
17:10
Most Chinese stocks in the US stock market rose before the market opened, with BeiGene (BGNE.O) up more than 6%, Bilibili (BILI.O) and Alibaba (BABA.N) up more than 4%. The 3x long FTSE China ETF-Direxion rose more than 4%.
17:02
Most of the popular Chinese stocks rose before the US market opened
Most of the popular Chinese stocks in the U.S. rose before the market opened, with BeiGene up more than 6%, Bilibili and Alibaba up more than 4%, Xpeng Motors up more than 3%, and Pinduoduo up more than 1%.
15:33
Hong Kong-listed biopharmaceutical stocks collectively strengthened, with BeiGene (06160.HK) rising more than 10%, Zai Lab (09688.HK) rising more than 9%, Tiger Pharmaceuticals (03347.HK) rising more than 8%, WuXi Biologics (02269.HK) rising more than 6%, WuXi AppTec (02359.HK) and Rongchang Biopharmaceuticals (09995.HK) rising more than 5%.
2025.02.15
05:44
HHLR Advisors, a subsidiary of Hillhouse Capital, disclosed that 8 of the top 10 US stock holdings in the fourth quarter were Chinese stocks
HHLR Advisors, an independent fund management platform under Hillhouse Capital that focuses on secondary market investment, announced its U.S. stock holdings data as of the end of the fourth quarter of 2024. The data shows that among the top ten holdings of HHLR Advisors in the fourth quarter, Chinese stocks accounted for eight seats. BeiGene and Alibaba are still the top two holdings, in addition to Pinduoduo, NetEase, Beike, Vipshop, Legend Biotech and Futu Holdings. The holdings show HHLR Advisors' continued focus on Chinese assets. Among the four stocks newly purchased by HHLR Advisors in the fourth quarter, two are Chinese stocks, namely Agora and Zhiwen Group (Momo). In the fourth quarter, HHLR Advisors increased its holdings of 10 stocks, of which four were Chinese stocks, namely JD.com, Beike, Futu Holdings and Dada Group.
2025.02.14
09:43
Hong Kong-listed biopharmaceutical stocks strengthened in early trading, with InnoCare Pharma (09969.HK) rising more than 6%, WuXi Biologics (02269.HK), BeiGene (06160.HK), WuXi AppTec (02359.HK), Rongchang Biopharma (09995.HK), and GenScript Biotech (01548.HK) all rising more than 5%, and Tiger Pharmaceuticals (03347.HK) rising more than 4.5%.
2025.01.20
09:36
The Hong Kong stock biopharmaceutical sector rose in early trading, with WuXi AppTec (02359.HK) rising more than 5%, WuXi Biologics (02269.HK) rising more than 4%, BeiGene (06160.HK), Tiger Pharmaceuticals (03347.HK) and others following suit.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Singapore investigates Nvidia server export fraud

2025-03-03

Shenzhen: By 2027, there will be more than 1,200 companies related to the embodied intelligent robot industry cluster

2025-03-03

Hongqi Chain Store: Deputy General Managers Zhang Ying, Wan Chun, Hong Fan and Yang Yuanbin resigned

2025-03-03

Shenzhen: Focus on supporting key core technologies such as core components of embodied intelligent robots, AI chips, and bionic dexterous hands

2025-03-03

Intel showcases Xeon 6 processor-based network infrastructure at MWC2025

2025-03-03

ASIA TECH WIRE

Grasp technology trends

Download